Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice

Annals of the New York Academy of Sciences

Volumn 1375, Issue 1, 2016, Pages 52-65

  Xue, Han ^a   Chen, Di ^a   Zhong, Yan Ke ^a   Zhou, Zhen Diao ^a   Fang, Shi Xin ^a   Li, Ming Yao ^a   Guo, Chuang ^a  

^a NORTHEASTERN UNIVERSITY   (China)

Author keywords

deferoxamine; iron; nonalcoholic fatty liver disease; ob ob mice

Indexed keywords

CASPASE 3; CYTOKINE; DEFEROXAMINE; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UNCOUPLING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BIOCHEMISTRY; BODY WEIGHT; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; FATTY LIVER; FOOD INTAKE; GLUCOSE BLOOD LEVEL; IRON CHELATION; IRON DEPLETION; IRON TRANSPORT; LIPID METABOLISM; LIVER LEVEL; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; OB/OB MOUSE; OBESITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84982840493     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13174     Document Type: Article

References (67)

1. Smith, B.W. & L.A. Adams. 2011. Non-alcoholic fatty liver disease. Crit. Rev. Clin. Lab. Sci. 48: 97–113.
2. Marchesini, G. et al. 2001. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50: 1844–1850.
3. Smith, B.W. & L.A. Adams. 2011. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat. Rev. Endocrinol. 7: 456–465.
4. Lomonaco, R. et al. 2013. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 73: 1–14.
5. Masuoka, H.C. & N. Chalasani. 2013. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann. N.Y. Acad. Sci. 1281: 106–122.
6. Bugianesi, E. et al. 2004. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39: 179–187.
7. George, D.K. et al. 1998. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114: 311–318.
8. Feldman, A. et al. 2015. The potential role of iron and copper in pediatric obesity and nonalcoholic fatty liver disease. Biomed. Res. Int. 2015: 287401.
9. Kim, Y.W. et al. 2009. Efficacy of sauchinone as a novel AMPK-activating lignan for preventing iron-induced oxidative stress and liver injury. Free Radic. Biol. Med. 47: 1082–1092.
10. Valenti, L. et al. 2007. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case–control study. Am. J. Gastroenterol. 102: 1251–1258.
11. Facchini, F.S., N.W. Hua & R.A. Stoohs. 2002. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122: 931–939.
12. Kaji, K. et al. 2011. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 300: G1094–G1104.
13. Aigner, E. et al. 2008. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 87: 1374–1383.
14. Ruivard, M. 2013. [Iron chelating therapy in adults: how and when?]. Rev. Med. Interne 34: 32–38.
15. Guo, C. et al. 2013. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34: 562–575.
16. Fine, J.M. et al. 2014. Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson's disease. Brain Res. 1574: 96–104.
17. Guo, C. et al. 2015. Intranasal deferoxamine attenuates synapse loss via up-regulating the P38/HIF-1α pathway on the brain of APP/PS1 transgenic mice. Front. Aging Neurosci. 7: 104.
18. Ward, R.J. et al. 2014. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 13: 1045–1060.
19. Tacchini, L. et al. 2008. Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. J. Biol. Chem. 283: 20674–20686.
20. Tajima, S. et al. 2011. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am. J. Physiol. Endocrinol. Metab. 302: E77–E86.
21. Bulucu, F. et al. 2009. Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol. Trace Elem. Res. 132: 184–196.
22. Dongiovanni, P. et al. 2008. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am. J. Pathol. 172: 738–747.
23. Sadrzadeh, S.M., P.E. Hallaway & A.A. Nanji. 1997. The long-acting parenteral iron chelator, hydroxyethyl starch–deferoxamine, fails to protect against alcohol-induced liver injury in rats. J. Pharmacol. Exp. Ther. 280: 1038–1042.
24. Zhang, Y. et al. 2014. Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice. Sci. Rep. 4: 7375.
25. Wang, C.Y. et al. 2013. Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of Alzheimer's disease. Antioxid. Redox Signal. 19: 2024–2039.
26. Sanches, S.C. et al. 2015. Nonalcoholic steatohepatitis: a search for factual animal models. Biomed. Res. Int. 2015: 574832.
27. Sun, K. et al. 2012. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc. Natl. Acad. Sci. U.S.A. 109: 5874–5879.
28. Memon, R.A. et al. 2000. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141: 4021–4031.
29. Uno, K. et al. 2006. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 312: 1656–1659.
30. Myers, D.A. et al. 2008. Long-term hypoxia modulates expression of key genes regulating adipose function in the late-gestation ovine fetus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R1312–R1318.
31. Syn, W.K., S.S. Choi & A.M. Diehl. 2009. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 565–580.
32. Rashid, A. et al. 1999. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 29: 1131–1138.
33. Begriche, K. et al. 2013. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 58: 1497–1507.
34. Sumida, Y., T. Yoshikawa & T. Okanoue. 2009. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol. Res. 39: 213–222.
35. Redaelli, C.A. et al. 2004. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J. Hepatol. 40: 305–312.
36. Sun, Y. et al. 2007. Liver proteome analysis of adaptive response in rat immediately after partial hepatectomy. Proteomics 7: 4398–4407.
37. Richard, D.E. et al. 1999. p42/p44 Mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274: 32631–32637.
38. 2-terminal kinase activation contributes to hypoxia-inducible factor 1α–dependent P-glycoprotein expression in hypoxia. Cancer Res. 64: 9057–9061.
39. Yu, X.X. et al. 2008. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. Am. J. Physiol. Endocrinol. Metab. 295: E436–E445.
40. Duscher, D. et al. 2015. Transdermal deferoxamine prevents pressure-induced diabetic ulcers. Proc. Natl. Acad. Sci. U.S.A. 112: 94–99.
41. Hou, Z. et al. 2013. Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α. Diabetes Res. Clin. Pract. 101: 62–71.
42. Jochheim-Richter, A. et al. 2006. Gene expression analysis identifies novel genes participating in early murine liver development and adult liver regeneration. Differentiation 74: 167–173.
43. Larter, C.Z. & M.M. Yeh. 2008. Animal models of NASH: getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 23: 1635–1648.
44. Selzner, N. et al. 2006. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J. Hepatol. 44: 694–701.
45. Chu, M.J. et al. 2014. Ob/ob mouse livers show decreased oxidative phosphorylation efficiencies and anaerobic capacities after cold ischemia. PLoS One 9: e100609.
46. Riquelme, A. et al. 2004. Histological resolution of steatohepatitis after iron depletion. Dig. Dis. Sci. 49: 1012–1015.
47. Kaji, K. et al. 2010. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 300: G1094–G1104.
48. Yu, S. et al. 2003. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression. J. Biol. Chem. 278: 498–505.
49. Minokoshi, Y. et al. 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339–343.
50. Lee, Y.M. et al. 2006. Effects of dietary genistein on hepatic lipid metabolism and mitochondrial function in mice fed high-fat diets. Nutrition 22: 956–964.
51. Winter, W.E., L.A. Bazydlo & N.S. Harris. 2014. The molecular biology of human iron metabolism. Lab. Med. 45: 92–102.
52. Videla, L.A. et al. 2003. Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells. Biometals 16: 103–111.
53. Gunton, J.E. et al. 2005. Loss of ARNT/HIF1β mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 122: 337–349.
54. Machado, M.V. & H. Cortez-Pinto. 2011. Cell death and nonalcoholic steatohepatitis: where is ballooning relevant? Expert Rev. Gastroenterol. Hepatol. 5: 213–222.
55. Panasiuk, A. et al. 2006. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J. Gastroenterol. 12: 6198–6202.
56. Seki, S. et al. 2002. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37: 56–62.
57. Schattenberg, J.M. et al. 2005. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J. Biol. Chem. 280: 9887–9894.
58. Ribeiro, P.S. et al. 2004. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 99: 1708–1717.
59. Kim, B. S. et al. 2002. Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death. Cell. Immunol. 220: 96–106.
60. Lee, S.K. et al. 2006. p38 and ERK MAP kinase mediates iron chelator-induced apoptosis and -suppressed differentiation of immortalized and malignant human oral keratinocytes. Life Sci. 79: 1419–1427.
61. Jin, H.O. et al. 2006. Up-regulation of Bak and Bim via JNK downstream pathway in the response to nitric oxide in human glioblastoma cells. J. Cell. Physiol. 206: 477–486.
62. Tuncman, G. et al. 2006. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 103: 10741–10746.
63. Jung, Y. & A.M. Diehl. 2010. Non-alcoholic steatohepatitis pathogenesis: role of repair in regulating the disease progression. Dig. Dis. 28: 225–228.
64. Zhan, L. et al. 2015. Hypoxia-inducible factor-1alpha in hepatic fibrosis: a promising therapeutic target. Biochimie 108: 1–7.
65. Manalo, D.J. et al. 2005. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105: 659–669.
66. Peyssonnaux, C., V. Nizet & R.S. Johnson. 2008. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 7: 28–32.
67. Selzner, M. & P.A. Clavien. 2000. Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. Hepatology 31: 35–42.